{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:47:22Z","timestamp":1773784042492,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40744-025-00821-2","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:15:15Z","timestamp":1769148915000},"page":"347-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03796858","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1834-2688","authenticated-orcid":false,"given":"Vilija","family":"Oke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9847-2996","authenticated-orcid":false,"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-257X","authenticated-orcid":false,"given":"Frederic","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"821_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"821_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:405\u201317.","journal-title":"Expert Rev Clin Immunol"},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40744-022-00436-x","volume":"9","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Myers K, Mansfield C, et al. Experiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower Registry. Rheumatol Ther. 2022;9:735\u201351.","journal-title":"Rheumatol Ther"},{"key":"821_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"821_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"821_CR6","doi-asserted-by":"publisher","first-page":"rky042","DOI":"10.1093\/rap\/rky042","volume":"2","author":"G Clunie","year":"2018","unstructured":"Clunie G, McInnes IB, Barkham N, et al. Long-term effectiveness of tumour necrosis factor-alpha inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatol Adv Pract. 2018;2:rky042.","journal-title":"Rheumatol Adv Pract"},{"key":"821_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000880","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5:e000880.","journal-title":"RMD Open"},{"key":"821_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/ced.15237","volume":"47","author":"Y Xie","year":"2022","unstructured":"Xie Y, Liu Y. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review. Clin Exp Dermatol. 2022;47:1627\u201335.","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl 10","key":"821_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/acr.24242","volume":"72","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):82\u2013109.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"821_CR10","first-page":"1188","volume":"34","author":"F Tubach","year":"2007","unstructured":"Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007;34:1188\u201393.","journal-title":"J Rheumatol"},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/acr.25111","volume":"75","author":"P Karmacharya","year":"2023","unstructured":"Karmacharya P, Stull C, Stephens-Shields A, et al. Responsiveness and minimum clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis: a prospective cohort study. Arthritis Care Res (Hoboken). 2023;75:2182\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81:359\u201369.","journal-title":"Ann Rheum Dis"},{"key":"821_CR13","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline. Guideline for good clinical practice E6(R3). 2025. Available at: https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf"},{"key":"821_CR14","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). General Methods Version 6.1; 2022. p. 174. Available at: https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-1.pdf"},{"key":"821_CR15","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811\u20139.","journal-title":"J Rheumatol"},{"key":"821_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38:2461\u20135.","journal-title":"J Rheumatol"},{"key":"821_CR17","unstructured":"Ware JE, Kosinski M, Keller SD, SF-36 Physical and Mental Health Summary Scales: a user\u2019s manual. Boston: Health Assessment Lab, New England Medical Center; 1994."},{"key":"821_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","volume":"22","author":"DP Lubeck","year":"2004","unstructured":"Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics. 2004;22:27\u201338.","journal-title":"Pharmacoeconomics"},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"821_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27\u201333.","journal-title":"Dermatology"},{"issue":"suppl 62","key":"821_CR21","first-page":"50","volume":"147","author":"FA Khilji","year":"2002","unstructured":"Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores [abstract P-59]. Br J Dermatol. 2002;147(suppl 62):50.","journal-title":"Br J Dermatol"},{"key":"821_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol. 2005;125:659\u201364.","journal-title":"J Investig Dermatol"},{"key":"821_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3899\/jrheum.181412","volume":"47","author":"M Skougaard","year":"2020","unstructured":"Skougaard M, Jorgensen TS, Rifbjerg-Madsen S, et al. Relationship between fatigue and inflammation, disease duration, and chronic pain in psoriatic arthritis: an observational DANBIO registry study. J Rheumatol. 2020;47:548\u201352.","journal-title":"J Rheumatol"},{"key":"821_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaad.2024.02.026","volume":"91","author":"L Nymand","year":"2024","unstructured":"Nymand L, Kristensen LE, Thomsen SF, et al. Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: a cross-sectional study. J Am Acad Dermatol. 2024;91:57\u201363.","journal-title":"J Am Acad Dermatol"},{"key":"821_CR25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1136\/ard.2008.098202","volume":"68","author":"JA Husted","year":"2009","unstructured":"Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis. 2009;68:1553\u20138.","journal-title":"Ann Rheum Dis"},{"key":"821_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405\u201317.","journal-title":"J Am Acad Dermatol"},{"key":"821_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331.","journal-title":"J Am Acad Dermatol"},{"key":"821_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394:831\u20139.","journal-title":"Lancet"},{"key":"821_CR29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185:1146\u201359.","journal-title":"Br J Dermatol"},{"issue":"6","key":"821_CR30","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40744-024-00702-0","volume":"11","author":"JR Curtis","year":"2024","unstructured":"Curtis JR, Deodhar A, Soriano ER, et al. Early improvements with guselkumab associate with sustained control of psoriatic arthritis: post hoc analyses of two phase 3 trials. Rheumatol Ther. 2024;11(6):1501\u20131517. https:\/\/doi.org\/10.1007\/s40744-024-00702-0.","journal-title":"Rheumatol Ther"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23:190.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"821_CR32","doi-asserted-by":"publisher","first-page":"e001321","DOI":"10.1136\/rmdopen-2020-001321","volume":"6","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Michaud K, Nowak M, et al. Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open. 2020;6(3):e001321. https:\/\/doi.org\/10.1136\/rmdopen-2020-001321.","journal-title":"RMD Open"},{"key":"821_CR33","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3899\/jrheum.161459","volume":"44","author":"W Tillett","year":"2017","unstructured":"Tillett W, Dures E, Hewlett S, et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J Rheumatol. 2017;44:1445\u201352.","journal-title":"J Rheumatol"},{"key":"821_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3899\/jrheum.220386","volume":"50","author":"LC Coates","year":"2023","unstructured":"Coates LC, van der Horst-Bruinsma IE, Lubrano E, et al. Sex-specific differences in patients with psoriatic arthritis: a systematic review. J Rheumatol. 2023;50:488\u201396.","journal-title":"J Rheumatol"},{"key":"821_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"821_CR36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936\u20139.","journal-title":"Ann Rheum Dis"},{"key":"821_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, Lowe B, Cella D, et al. General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. Value Health. 2018;21:1313\u201321.","journal-title":"Value Health"},{"key":"821_CR38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528\u201338.","journal-title":"Cancer"},{"key":"821_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jpainsymman.2009.12.016","volume":"40","author":"Z Butt","year":"2010","unstructured":"Butt Z, Rao AV, Lai JS, et al. Age-associated differences in fatigue among patients with cancer. J Pain Symptom Manag. 2010;40:217\u201323.","journal-title":"J Pain Symptom Manag"},{"key":"821_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.","journal-title":"Health Qual Life Outcomes"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00821-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:05:57Z","timestamp":1773770757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00821-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00821-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laure Gossec: research grants: AbbVie, Eli Lilly, Novartis, UCB; consulting fees: AbbVie, AlfaSigma, Amgen, Bristol Myers Squibb, Celltrion, Eli Lilly, Johnson & Johnson, Moonlake, Novartis, Pfizer, Stada, UCB; non-financial support: AbbVie, Amgen, Biogen, Celltrion, Johnson & Johnson, Pfizer, UCB. Xenofon Baraliakos: speakers bureau: AbbVie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, and UCB; consultant of: AbbVie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, and UCB; grant\/research support: AbbVie, Eli Lilly, Johnson & Johnson, MSD, Novartis. James Galloway: consulting fees, grant\/research support, and speakers bureau: AbbVie, Alfasigma, Eli Lilly, Galapagos, Johnson & Johnson, Novartis, Pfizer, and UCB. Vilija Oke: consulting fees: AbbVie, Eli Lilly, Johnson & Johnson, Novartis, AstraZeneca, and UCB. Research grant from ONO Pharma. Petros Sfikakis: consulting fees and grant\/research support: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli-Lilly, Johnson & Johnson, Novartis, UCB, and Pfizer. Emmanouil Rampakakis: employee: JSS Medical Research; paid consultant of: Johnson & Johnson. Mohamed Sharaf: employee: Johnson & Johnson; shareholder of: Johnson & Johnson. Frederic Lavie: employee: Johnson & Johnson at the time this work was performed and currently an employee of Les Entreprises du M\u00e9dicament, Paris, France; shareholder of Johnson & Johnson. Iain B. McInnes: consulting fees: AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, Glaxo Smith Kline, Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi, and UCB; grant\/research support: Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Novartis, Roche, and UCB; shareholder: Causeway, and Evelo Compugen; NHS GGC Board Member; Evelo Board of Directors; and Versus Arthritis Trustee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The COSMOS study was conducted in accordance with principles of the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice. Each site\u2019s ethical body approved the study protocol, and all participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}